 Connection
Theodore Karrison to Myelodysplastic Syndromes
This is a "connection" page, showing publications Theodore Karrison has written about Myelodysplastic Syndromes.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.415 |
|
|
|
-
Karrison T, Archer KJ, Espinosa R, Wen M, Huo D. Data management and statistical methods used in the analysis of balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and therapy-related acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):346-61.
Score: 0.182
-
Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM. Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 2016 06; 101(6):e232-6.
Score: 0.120
-
Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JW. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
Score: 0.064
-
Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
Score: 0.049
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|